Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus

Ablasser, 2013, Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP, Nature, 503, 530, 10.1038/nature12640 Bonilla-Martinez, 2008, The Cutaneous Lupus Erythematosus Disease Area and Severity Index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus, Arch Dermatol, 144, 173, 10.1001/archderm.144.2.173 Chan, 2015, Ruxolitinib attenuates cutaneous lupus development in a mouse lupus model, J Invest Dermatol, 135, 2338, 10.1038/jid.2015.216 Chi, 2014, Cathelicidin antimicrobial peptide LL-37 in cholesteatoma enables keratinocyte reactivity with cytosolic DNA, Scand J Immunol, 79, 214, 10.1111/sji.12149 Chiliveru, 2014, Inflammatory cytokines break down intrinsic immunological tolerance of human primary keratinocytes to cytosolic DNA, J Immunol, 192, 2395, 10.4049/jimmunol.1302120 Chow, 2015, PRRs are watching you: localization of innate sensing and signaling regulators, Virology, 479–480, 104, 10.1016/j.virol.2015.02.051 Ding, 2015, The regional function of cGAS/STING signal in multiple organs: one of culprit behind systemic lupus erythematosus?, Med Hypotheses, 85, 846, 10.1016/j.mehy.2015.09.026 Gall, 2012, Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease, Immunity, 36, 120, 10.1016/j.immuni.2011.11.018 Gao, 2015, Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases, Proc Natl Acad Sci USA, 112, E5699, 10.1073/pnas.1516465112 Gehrke, 2013, Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing, Immunity, 39, 482, 10.1016/j.immuni.2013.08.004 Grieves, 2015, Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease, Proc Natl Acad Sci USA, 112, 5117, 10.1073/pnas.1423804112 Kalali, 2008, Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-mediated differential signaling, J Immunol, 181, 2694, 10.4049/jimmunol.181.4.2694 Klaeschen, 2016, Upcoming therapeutic targets in cutaneous lupus erythematous, Expert Rev Clin Pharmacol, 9, 567, 10.1586/17512433.2016.1145543 Kreuter, 2011, Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus, J Am Acad Dermatol, 65, 125, 10.1016/j.jaad.2010.12.012 Kuhn, 2016, Lupus erythematosus revisited, Semin Immunopathol, 38, 97, 10.1007/s00281-015-0550-0 Kuhn, 2014, Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review, Clin Rev Allergy Immunol, 47, 148, 10.1007/s12016-013-8403-x Kunz, 2015, Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus, Exp Dermatol, 24, 510, 10.1111/exd.12708 Li, 2014, Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36gamma induction in human epidermal keratinocytes, J Immunol, 193, 5140, 10.4049/jimmunol.1302574 Liu, 2012, Taming lupus-a new understanding of pathogenesis is leading to clinical advances, Nat Med, 18, 871, 10.1038/nm.2752 Lu, 2017, The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis, J Autoimmun, 78, 46, 10.1016/j.jaut.2016.12.003 Mahajan, 2016, Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE, Front Immunol, 7, 35, 10.3389/fimmu.2016.00035 Peschke, 2014, Deregulated type I IFN response in TREX1-associated familial chilblain lupus, J Invest Dermatol, 134, 1456, 10.1038/jid.2013.496 Ronnblom, 2013, The interferon signature in autoimmune diseases, Curr Opin Rheumatol, 25, 248, 10.1097/BOR.0b013e32835c7e32 Smith, 2014, Role of DNA/RNA sensors and contribution to autoimmunity, Cytokine Growth Factor Rev, 25, 745, 10.1016/j.cytogfr.2014.07.019 Wenzel, 2007, Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches, Exp Dermatol, 16, 454, 10.1111/j.1600-0625.2007.00556.x Wenzel, 2008, An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in “interface dermatitis”, J Invest Dermatol, 128, 2392, 10.1038/jid.2008.96 Wenzel, 2016, JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus, J Invest Dermatol, 136, 1281, 10.1016/j.jid.2016.02.015 Wenzel, 2005, Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus, J Pathol, 205, 435, 10.1002/path.1721 Wenzel, 2007, The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets, Br J Dermatol, 157, 752, 10.1111/j.1365-2133.2007.08137.x Zahn, 2014, Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus, Exp Dermatol, 23, 516, 10.1111/exd.12428 Zahn, 2011, Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus, J Invest Dermatol, 131, 133, 10.1038/jid.2010.244